Halozyme Therapeutics (HALO) Financials

$109.66

$1.94 (1.80%)

As on 02-Sep-2026 16:00EDT

Market cap

$11,957 Mln

Revenue (TTM)

$1,664 Mln

P/E Ratio

30.9

P/B Ratio

84.5

Div. Yield

0 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	1,663.74	1,396.61	1,015.32	829.25	660.12	443.31
Cost of Revenue	363.07	305.44	159.42	192.36	139.30	81.41
Gross Profit	1,300.67	1,091.18	855.91	636.89	520.81	361.90
Operating Expenses	356.18	274.88	304.43	299.32	253.28	86.00
Operating Profit (EBIT)	944.49	816.29	551.48	337.57	267.53	275.90
Other Income	--	--	--	--	-1.67	-19.86
Profit before Tax	583.34	466.88	557.13	348.33	248.92	248.52
Provision for Tax	169.74	149.99	113.04	66.74	46.79	-154.19
Profit after Tax (Net Income)	413.60	316.89	444.09	281.59	202.13	402.71
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	202.13	402.71

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	143.54	48.81	363.82	83.81	169.80	196.95
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	2,089.43	2,299.42	1,560.56	1,536.97	1,540.92	790.33
Current Liabilities	344.44	177.09	139.10	112.49	130.79	117.15
Total Liabilities	2,921.85	2,525.32	2,063.48	1,733.27	1,841.51	1,104.43

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	1,644.38	1,700.12	978.14	986.85	1,102.50	178.14
Current Assets	933.02	825.21	1,085.34	746.42	739.01	926.29
Total Assets	2,921.85	2,525.32	2,063.48	1,733.27	1,841.51	1,104.43
Total Debt*	2,146.65	2,142.63	1,505.80	1,499.25	1,506.10	876.67
Net Current Assets	588.59	648.12	946.24	633.93	608.22	809.14

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	651.56	479.06	388.57	240.11	299.44
Cash Flow from Investing Activities	--	-545.81	-262.72	-96.91	-487.01	-406.29
Cash from Financing Activities	--	-85.17	-218.86	-407.99	362.37	77.87
Net Cash Inflow / Outflow	--	--	--	--	115.48	-28.98

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	3.35	2.69	3.43	2.15	1.46	2.79
Cash EPS ($)	--	3.44	4.06	2.80	1.82	2.81
Adjusted Book Value ($)	--	0.41	2.81	0.64	1.23	1.37
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	5.54	3.70	2.97	1.73	2.08
Free Cash Flow per Share ($)	--	5.48	3.62	2.85	1.70	2.07

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	15.61	25.72	17.28	14.70	49.66
ROE (%)	430.03	153.59	198.42	222.07	110.23	231.44
ROA (%)	16.19	13.81	23.39	15.75	13.72	47.82
EBIT Margin (%)	36.28	34.73	56.65	44.27	40.28	62.24
Net Margin (%)	24.86	22.69	43.74	33.96	30.70	95.10
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	41.15	0.38	0.22	0.26	0.49	0.66
EBIT Growth (%)	-14.99	-15.69	56.70	38.07	-3.64	91.26
Net Profit Growth (%)	-25.78	-28.64	57.71	39.31	-49.81	211.97
EPS Growth (%)	-23.48	-0.22	0.60	0.47	-0.48	2.14
Book Value Growth (%)	-55.81	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	30.89	24.99	13.93	17.20	39.02	14.40
Price / Book Value	84.52	162.23	17.01	57.79	46.45	29.45
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	19.55	17.31	10.81	13.29	28.62	21.28
Close Price ($)	78.27	67.30	47.81	36.96	56.90	40.21
High Price ($)	82.22	79.50	65.53	57.10	59.46	56.40
Low Price ($)	51.78	47.50	33.15	29.85	31.36	31.79
Market Cap ($ Cr)	11,957.01	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	13.50	43.89	4.14	17.89	8.87	4.45
Short term debt to equity ratio	1.46	--	--	0.08	0.08	0.45
Current Ratio	2.71	4.66	7.80	6.64	5.65	7.91
Quick Ratio	2.31	3.66	6.78	5.50	4.88	7.45
Interest Coverage	29.73	26.76	31.79	19.57	15.69	36.66

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	27.40	31.60	30.38	28.24	35.00	20.52
Asset Turnover	0.65	0.61	0.53	0.46	0.45	0.53
Receivable days	--	98.04	97.61	102.47	89.10	77.74
Inventory Days	--	190.34	308.69	216.20	201.93	257.19
Payable days	--	18.62	25.28	28.02	25.22	7.78
Cash Conversion Cycle	--	269.75	381.02	290.65	265.81	327.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)